8th Annual MarketsandMarkets

Next-Gen Immuno-Oncology Conference

07th - 8th March 2024

Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

Leading the Immunotherapy Revolution: Pioneering Advances in Immuno-Oncology

Welcome to the 8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference, a premier event dedicated to advancing the field of immuno-oncology. Join us on 07th - 8th March 2024 in London, UK, where leading experts, researchers, and industry professionals will gather to shape the future of cancer treatment.

As a prominent Immuno-Oncology Conference, this event offers a unique platform to explore the latest advancements, breakthroughs, and innovations in the field. From antibodies and cellular therapies to immune-checkpoint research, our comprehensive program covers a wide range of topics, ensuring a holistic understanding of the dynamic landscape of immuno-oncology.

Engage in interactive sessions, insightful panel discussions, and thought-provoking keynote speeches delivered by renowned speakers. Contribute to interactive roundtables, where you can deliberate on key topics that are most relevant to your field. Exchange knowledge, network with peers, and foster collaborations with experts from around the world, as we collectively strive to drive progress and inspire hope in the fight against cancer.

CO-LOCATED CONFERENCES

5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

NEW ANTIBODIES DEVELOPMENTS AND UPDATES

Keynote Presentation- HLA-agnostic T-cell recognition of cancer

Andrew Sewell

Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University

09:00 - 09:30

IgE Immunotherapy from Concept to Translation

Sophia Karagiannis

Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

09:30 - 10:00

PD-L1

Anne-Sophie Pailhes-Jimenez

Anne-Sophie Pailhes-Jimenez, R&D Director, ANGLE Europe Limited

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Targeting myeloid cells to augment antibody immunotherapy

Ali Roghanian

Ali Roghanian, PhD, FHEA | Associate Prof in Cancer Immunotherapy | BM Research Project Deputy Module Leader, Centre for Cancer Immunology | Faculty of Medicine | University of Southampton

11:15 - 11:45

From Biomarker Discovery to Diagnostic: Navigating the Translational Journey

Valerie Balme

Valerie Balme, Associate Director, Business Development, Biopharma

11:45 - 12:15

Fc Engineering to overcome suppressive tumour microenvironments

Stephen Beers

Stephen Beers, Professor, Immunology and Immunotherapy, University of Southampton

12:15 - 12:45

Preclinical mouse models for I/O research

Jianming Xu

Jianming Xu, Director, InVivo Pharmacology, GemPharmatech

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

NEW ANTOBODY FORMATS & CELL THERAPY

Gamma delta T cells as cancer immunotherapeutics

Jonathan Fisher

Jonathan Fisher, T-Cell Immunotherapy, Group Leader, University College London

14:15 - 14:45

A novel redirecting antibody targeting SCLC

Lindy Durrant

Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK

14:45 - 15:15

Boosting Cancer Therapy in immunotherapy with next microbiome generation co-cultured product

Nathalie Corvaia

Nathalie Corvaia, Chief Scientific Officer, MaaT Pharma

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Tumour micro environment and CAR-T Cell Therapy

Etienne De Braekeleer

Etienne De Braekeleer, Senior Scientist - Cell Biology & Research Immunology, AstraZeneca

16:30 - 17:00

iPSC derived cell therapies for the treatment of cancer

Michael Epstein

Michael Epstein, VP, Head of Translational Research in Innovate Oncology , Evotec

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Drinks Reception & Networking .....End of Day 1.....

17:30 - 17:30

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:50 - 09:00

CAR-T CELL THERAPY DEVELOPMENTS AND UPDATES

Keynote Presentation- CAR T-cell immunotherapy of solid tumours: moving through the generations

John Maher

John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio

09:00 - 09:30

A novel Neuropilin-1 (NRP1) antisense oligonucleotide (ASO) with strong in vivo antitumor activity as single agent and in combination with immune checkpoint inhibitors

Konstantin Petropoulos

Konstantin Petropoulos, Chief Business Officer, Secarna Pharmaceuticals

09:30 - 10:00

Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment

Mark Eccleston

Mark Eccleston, Chief Technology Officer, Volition

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Precise spatial multiplexing with ChipCytometry: An open-source solution to high-throughput spatial biology

Anders Eriksson

Anders Eriksson, Lead Field Application Scientist , Canopy Biosciences

11:15 - 11:45

....

Farzin Farzaneh

Farzin Farzaneh, CSO, ViroCell Biologics Ltd

11:45 - 12:15

...

Joanna Brewer

Joanna Brewer, Chief Scientific Officer, Adaptimmune

12:15 - 12:45

T cell mechanostimulation as a promising approach for enhancing immunotherapies

Sebastian Lickert

Sebastian Lickert, Group Lead, ETH Zürich

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

NEW CHECKPOINTS FOR IO-PERSONALIZED IMMUNOTHERAPY

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

14:15 - 14:45

Monocytes and Macrophages in Ovarian Cancer, Biomarker and therapeutic Opportunities in their Overlooked immune Checkpoints

Fernando Oneissi Martinez Estrada

Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey

14:45 - 15:15

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

Eric Halioua

Eric Halioua, President & CEO, PDC*line Pharma

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

....

Phillip Brailey

Phillip Brailey, Senior Scientist, Crescendo Biologics

16:30 - 17:00

Anti-CD270 antibody checkpoint inhibitor for cancer treatment: Swing around patient’s CD270 immunosuppressive disadvantage

Louis Boon

Louis Boon, CSO , JJP Biologics

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Drinks Reception & Networking .....End of Day 1.....

17:30 - 17:30

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

PRE-CLINICAL AND TRANSLATIONAL IO DEVELOPMENTS-PERSONALIZED CANCER IMMUNOTHERAPY

Keynote Presentation: Cross Training technology: augmenting cross-presentation of neo-antigens

Raj Mehta

Raj Mehta, Founder, Chief Executive Officer & Director, Adendra Therapeutics

09:00 - 09:30

Personalized Immunotherapies: Past, Present and Future

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

09:30 - 10:00

Unlocking IL-2 therapeutic power using Attenukine™ platform

Iris Hecht

Iris Hecht, Sr. Director, Project Leader, Specialty Projects, Teva

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

LATEST DEVELOPMENTS & TRENDS IN IO RESEARCH

Generative AI designed Personalized Neoantigen Vaccines

Daniela Kleine-Kohlbrecher

Daniela Kleine-Kohlbrecher, Senior Project Manager Immune Oncology, Evaxion Biotech

11:15 - 11:45

Exploring γδT Reprogramming as a Solution for Donor Material Access and Donor-to-Donor Variability

Daria Paruzina

Daria Paruzina, Senior Manager of Product Development and Platform Expansion, TC BioPharm

11:45 - 12:15

Cross Training technology: augmenting cross-presentation of neo-antigens

Raj Mehta

Raj Mehta, Founder, Chief Executive Officer & Director, Adendra Therapeutics

12:15 - 12:45

Cancer Vaccines: bringing safety and specificity to immunotherapy

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

John Maher

John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Louis Boon

Louis Boon, CSO , JJP Biologics

14:15 - 14:45

Closing Remarks from the Chairperson

14:45 - 14:50

END OF CONFERENCE

14:50 - 14:50

SPEAKERS

Louis Boon

Louis Boon

CSO , JJP Biologics

Senior Director, Head of R&D

Senior Director, Head of R&D

,

John Maher

John Maher

Scientific Founder and Chief Scientific Officer, Leucid Bio

Daria Paruzina

Daria Paruzina

Senior Manager of Product Development and Platform Expansion, TC BioPharm

Michael Epstein

Michael Epstein

VP, Head of Translational Research in Innovate Oncology , Evotec

Jonathan Fisher

Jonathan Fisher

T-Cell Immunotherapy, Group Leader, University College London

Andrew Pierce

Andrew Pierce

Vice President, Translational Biology, Crescendo Biologics

Lindy Durrant

Lindy Durrant

Professor, Cancer Immunotherapy, University of Nottingham, UK

Sebastian Lickert

Sebastian Lickert

Group Lead, ETH Zürich

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Joanna Brewer

Joanna Brewer

Chief Scientific Officer, Adaptimmune

Phillip Brailey

Phillip Brailey

Senior Scientist, Crescendo Biologics

Pedro Correa de Sampaio

Pedro Correa de Sampaio

Co-Founder, CEO,, Neobe Therapeutics

Anders Eriksson

Anders Eriksson

Lead Field Application Scientist , Canopy Biosciences

Eric Halioua

Eric Halioua

President & CEO, PDC*line Pharma

Raj Mehta

Raj Mehta

Founder, Chief Executive Officer & Director, Adendra Therapeutics

Elizabeth Sheppard

Elizabeth Sheppard

Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

John Maudsley

John Maudsley

CEO, Cancer Vaccines Ltd

Jianming Xu

Jianming Xu

Director, InVivo Pharmacology, GemPharmatech

Farzin Farzaneh

Farzin Farzaneh

CSO, ViroCell Biologics Ltd

Stephen Beers

Stephen Beers

Professor, Immunology and Immunotherapy, University of Southampton

Andrew Sewell

Andrew Sewell

Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University

Ali Roghanian

Ali Roghanian

PhD, FHEA | Associate Prof in Cancer Immunotherapy | BM Research Project Deputy Module Leader, Centre for Cancer Immunology | Faculty of Medicine | University of Southampton

Valerie Balme

Valerie Balme

Associate Director, Business Development, Biopharma

Daniela Kleine-Kohlbrecher

Daniela Kleine-Kohlbrecher

Senior Project Manager Immune Oncology, Evaxion Biotech

Konstantin Petropoulos

Konstantin Petropoulos

Chief Business Officer, Secarna Pharmaceuticals

Iris Hecht

Iris Hecht

Sr. Director, Project Leader, Specialty Projects, Teva

Etienne De Braekeleer

Etienne De Braekeleer

Senior Scientist - Cell Biology & Research Immunology, AstraZeneca

Bryan Kobel

Bryan Kobel

Chief Executive Officer, TC Biopharm

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Mark Eccleston

Mark Eccleston

Chief Technology Officer, Volition

Senior Representative Canopy Biosciences

Senior Representative Canopy Biosciences

Senior Representative Canopy Biosciences,

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

PAST EVENT GALLERY